Paid-in Capital Increase Amendment: Shares Up, Price Down
젬백스
082270
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2740
Risk-adjusted indicator based on 2740 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • New Shares (Amended): 1,384,439 Shares (Previously: 642,236 Shares)
- • Issuance Price (Amended): 11,557 KRW/Share (Previously: 26,470 KRW/Share)
- • Funding Size (Amended): 15,999,961,523 KRW (Previously: 16,999,986,920 KRW)
- • Dilution Rate (Amended): ~10.9% (Based on 12,690,000 existing shares)
- • Operating Funds for R&D/Raw Materials: 16,000M KRW
AI Analysis Summary
GemVax & KAEL Co.,Ltd. announced an amendment to its paid-in capital increase. The number of new shares to be issued increased significantly from 642,236 to 1,384,439 shares, while the issuance price per share was revised downwards from 26,470 KRW to 11,557 KRW. The total funding size decreased slightly from 16.99B KRW to 15.99B KRW, allocated for R&D (8,000M KRW) and environmental business raw materials (8,000M KRW). This amendment implies a higher dilution rate for existing shareholders, estimated at approximately 10.9% based on the previous 12,690,000 outstanding shares, and a lower per-share value for the new issuance. The change in issuance price and increased share count are negative for existing shareholders.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.